亿帆医药（002019）8月14日主力资金净流出1922.35万元

Group 1 - The core viewpoint of the news is that Yifan Pharmaceutical (亿帆医药) has shown a slight decline in stock price while reporting modest revenue growth and significant profit increases in its latest financial results [1][3] - As of August 14, 2025, Yifan Pharmaceutical's stock closed at 15.3 yuan, down 1.29%, with a trading volume of 221,200 hands and a transaction amount of 342 million yuan [1] - The company's total revenue for the first half of 2025 was 2.635 billion yuan, a year-on-year increase of 0.11%, while net profit attributable to shareholders was 304 million yuan, up 19.91% [1] Group 2 - The company has a current ratio of 1.308, a quick ratio of 0.912, and a debt-to-asset ratio of 31.70% [1] - Yifan Pharmaceutical has made investments in 18 companies and participated in 5 bidding projects, indicating active engagement in business development [2] - The company holds 23 trademark registrations and 11 patents, along with 12 administrative licenses, showcasing its commitment to innovation and compliance [2]